Avingtrans Plc (LON:AVG) has taken another significant step forward in its medical technology ambitions after securing CE certification for the Adaptix Ortho350 system, according to the latest research note from Singer Capital Markets.
The certification opens the door for the company to commercialise the Ortho350 across the UK and Europe, following US FDA clearance received in November 2025. Together, these approvals mean the product can now be marketed in two of the world’s most important healthcare markets.
Singer Capital Markets maintained its Buy rating on Avingtrans, with a 770p target price, highlighting growing confidence in the company’s medical division and broader long term strategy.
The Adaptix Ortho350 is a compact, portable 3D Digital Tomosynthesis imaging system designed for point of care use. The device focuses on orthopaedic imaging and can produce detailed low dose 3D scans of extremities including hands, elbows, shoulders, knees and feet. According to the broker, the system offers “superior diagnostic clarity versus traditional 2D X-ray at a fraction of CT radiation doses”.
Singer Capital Markets analysts Caroline de La Soujeole and Henry Carver described the CE approval as “a key milestone in the validation of Adaptix’s orthopaedics product, opening up the UK and European markets and strengthening our confidence in the path ahead.”
The broker recently attended a site visit with Adaptix management and came away with increased confidence in the roadmap for Avingtrans’ medical division, which includes Adaptix, Magnetica and Scientific Magnets.
Importantly, the analysts highlighted management’s ambition for the division to become “a $150m+ turnover highly diversified X-ray and magnetics company with strong positions in orthopaedic imaging, quantum computing, and industrial inspection” by 2031.
Commercial Momentum Building
Singer Capital Markets noted that Adaptix is making encouraging progress with its commercial strategy. The focus currently includes key opinion leader installations, clinical case studies, insurance coding validation and securing initial sales.
The analysts stated: “The commercial proposition for Ortho350 looks credible, based on helping healthcare providers release CT/MRI capacity and improved economics through higher reimbursement and reduced referrals.”
This positioning could prove particularly relevant as healthcare systems continue to look for ways to reduce imaging bottlenecks while lowering costs and radiation exposure for patients.
Alongside Adaptix, the broker also highlighted progress across the wider medical technology portfolio.
Magnetica was described as occupying “a clear niche between low quality sub-1T systems and expensive full body 3T machines”, although Singer noted the project remains at an earlier stage, with FDA submission expected in December 2026 and first product sales potentially arriving from Easter 2027.
Scientific Magnets, meanwhile, continues to benefit from increasing investment into quantum computing infrastructure. Singer noted that the business recently shipped its 20th superconducting magnet for quantum computing applications.
The broker also pointed to the UK Government’s recently announced £2 billion support package for quantum computing development, underlining the growing strategic importance of the sector.
Financial Highlights
Singer Capital Markets forecasts continued growth for Avingtrans over the next two years. Key forecasts from the research note include:
- Revenue expected to rise from £156.4 million in FY2025 to £175.0 million in FY2026
- Adjusted EBITDA forecast to increase from £16.6 million to £20.5 million
- Adjusted EPS expected to grow from 24.0p to 30.5p
- FY2027 revenue forecast of £193.2 million
- FY2027 adjusted EBITDA forecast of £24.6 million
The company’s shares had risen strongly over the previous 12 months, with the note showing an absolute return of 77.8% over the period.
Final Thoughts
The latest update from Singer Capital Markets suggests Avingtrans plc is steadily delivering on its strategy to build a diversified advanced engineering and medical technology group. The CE certification for Adaptix Ortho350 represents an important commercial milestone and provides another sign that the company’s investment into healthcare imaging technologies is beginning to gain traction in major international markets.
With regulatory approvals now secured in both Europe and the United States, investors will likely be watching closely for further commercial progress, additional installations and evidence of growing customer adoption during the months ahead.
